Wegovy strengths for weight loss: what each dose actually does

The myth that trips most people up: 'I should be on the highest dose from the start'

It is a reasonable instinct. If 2.4 mg produces more weight loss than 0.25 mg, why spend months at the lower end? The answer is tolerability. Semaglutide works partly by slowing how quickly your stomach empties, and that mechanism is what causes nausea, vomiting and digestive discomfort, side effects that hit hardest when the dose rises too quickly. The escalation schedule is not a formality; it is the structure that makes the medicine liveable for most people. Patients who skip doses or push titration timelines early end up stopping treatment altogether far more often than those who follow the plan. A prescription is required precisely because a prescriber needs to judge whether your body is ready to move up, not whether the calendar says four weeks have passed.

If you want to understand how the Wegovy dose is used for weight loss and why each stage is structured the way it is, the Wegovy dosage guide on this site walks through each step and what to expect at each level.

What the six Wegovy strengths actually do at each stage

The 0.25 mg weekly dose is the adjustment phase. Most prescribers and the NHS describe it clearly: this first pen's job is to settle your system, not to drive weight loss. You may notice a small reduction in appetite, but the therapeutic effect is minimal at this level. The 0.5 mg and 1.0 mg doses mark the transition into meaningful appetite suppression; for some people, weight loss becomes noticeable here. The 1.7 mg dose is the penultimate step before the standard 2.4 mg maintenance dose, which is where the bulk of the STEP 1 trial data sits. In that 68-week study, participants on 2.4 mg lost an average of around 15% of their body weight, as reported in the STEP 1 paper published in the New England Journal of Medicine.

Then there is the 7.2 mg dose, which is genuinely new territory. The MHRA approved a dedicated single-dose 7.2 mg Wegovy pen on 14 April 2026, one pre-set weekly injection with a covered, auto-locking needle. Trials at this strength reported approximately 20.7% average weight reduction over 72 weeks, bringing it closer to the results seen with tirzepatide at its highest dose. The 7.2 mg Wegovy pen page covers what that approval means in practice and who it applies to. Crucially, this dose is only licensed for adults with a BMI of 30 or above; it is not available for the cardiovascular indication, and the starting dose remains 0.25 mg regardless, there is no shortcut to 7.2 mg. Store whatever pen you are on in the fridge door where you will see it; the visual cue matters more than a calendar reminder for most people.

Which strength fits which stage of treatment, and what the prescriber weighs up

Eligibility for Wegovy in the UK requires a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of that determines your dose, though; dose is set by how you tolerate each step. A prescriber reviewing a repeat prescription is not just confirming you have lost weight, they are checking whether you have had persistent nausea, any signs of pancreatitis (severe stomach pain radiating toward the back is the red flag to act on immediately), or other signals that the current or next dose needs reconsideration. The NHS semaglutide page sets out the side-effect profile clearly, and the full dosing detail lives in the Patient Information Leaflet that comes with your pen.

For context on how Wegovy sits in the broader private weight-loss landscape, the weight-loss treatment overview on this site covers both semaglutide and tirzepatide options. NICE's recommendation for Wegovy (TA875) applies within specialist NHS weight management services for a maximum of two years; private prescribing follows the licensed criteria in the SmPC rather than TA875's NHS-only conditions. You can read the full NICE appraisal for semaglutide (TA875) if you want the committee's reasoning on when the NHS considers it appropriate. The cost of Wegovy in the UK varies by dose and provider; what matters for your safety is that any legitimate private service includes a clinical assessment and prescriber oversight, not just a price per pen.

What happens when the maintenance dose does not deliver enough, and what is next

NICE's guidance notes that if someone loses less than 5% of body weight after six months on the maintenance dose, continuing treatment should be reviewed. That does not mean the answer is necessarily a higher dose; it may mean reassessing the overall approach, including lifestyle factors, or considering whether a different medicine is more suitable. The Wegovy strength selector page explores what factors a prescriber considers, and the full Wegovy overview covers the licensed indications, mechanism and how it compares with alternatives. For people who do not respond adequately to 2.4 mg and meet the criteria, titration to 7.2 mg may be considered, but that is a clinical decision, made with evidence, not a self-upgrade. If you are weighing whether Wegovy is the right fit for you, our prescribers are the right people to ask. Start your free consultation and a GPhC-registered Independent Prescriber will review your case the same day.